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MaBACKGROUND Scientific guidelines consider atrial fibrillation (AF) complicating degenerative mitral regurgitation
(DMR) a debated indication for surgery.
OBJECTIVES This study analyzed the prognostic/therapeutic implications of AF at DMR diagnosis and long-term.
METHODS Patients were enrolled in the MIDA (Mitral Regurgitation International Database) registry, which reported
the consecutive, multicenter, international experience with DMR due to flail leaflets echocardiographically diagnosed.
RESULTS Among 2,425 patients (age 67  13 years; 71% male, 67% asymptomatic, ejection fraction 64  10%), 1,646
presented at diagnosis with sinus rhythm (SR), 317 with paroxysmal AD, and 462 with persistent AF. Underlying
clinical/instrumental characteristics progressively worsened from SR to paroxysmal to persistent AF. During follow-up,
paroxysmal and persistent AF were associated with excess mortality (10-year survival in SR and in paroxysmal and
persistent AF was 74  1%, 59  3%, and 46  2%, respectively; p < 0.0001), that persisted 20 years post-diagnosis
and independently of all baseline characteristics (p values <0.0001). Surgery (n ¼ 1,889, repair 88%) was associated
with better survival versus medical management, regardless of all baseline characteristics and rhythm (adjusted
hazard ratio: 0.26; 95% confidence interval: 0.23 to 0.30; p < 0.0001) but post-surgical outcome remained affected by
AF (10-year post-surgical survival in SR and in paroxysmal and persistent AF was 82  1%, 70  4%, and 57  3%,
respectively; p < 0.0001).
CONCLUSIONS AF is a frequent occurrence at DMR diagnosis. Although AF is associated with older age and more
severe presentation of DMR, it is independently associated with excess mortality long-term after diagnosis. Surgery is
followed by improved survival in each cardiac rhythm subset, but persistence of excess risk is observed for each type of
AF. Our study indicates that detection of AF, even paroxysmal, should trigger prompt consideration for surgery.
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265AB BR E V I A T I O N S
AND ACRONYM S
AF = atrial fibrillation
CVD = cardiovascular death
DMR = degenerative mitral
regurgitation
SR = normal sinus rhythmD egenerative mitral regurgitation (DMR) isthe most prevalent moderate/severevalvular heart disease (1), which leads to
frequent hospitalizations and cardiac surgery (2),
but often remains untreated (3) despite specific
criteria defined by clinical guidelines (4,5). In parallel
to DMR, atrial fibrillation (AF) is also prevalent with
aging, is associated with notable risks, and is a
burden for health care systems worldwide (6–10).
Although most cases of AF are nonvalvular, DMR
can cause AF because DMR-induced volume overload
leads to left atrial enlargement and, eventually, AF
(11,12).SEE PAGE 275These important epidemiological and pathophysi-
ological data call for more effective strategies
aimed at treating and possibly preventing
the consequences of these 2 diseases (3). Nowadays,
innovative technologies ranging from robotic surgery
to percutaneous repair or replacement can provide
previously unimagined treatment opportunities, but
conversely render risk assessment in DMR even more
crucial (13). Surprisingly, AF’s prognostic impact in
DMR remains widely debated as it is often found to be
insignificant (14–17) or at other times important
(11,18,19). These inconsistencies may be caused by
small sample sizes (14,15,18,20), or single-center
studies (11,14,15,18) of inconsistent regurgitation eti-
ology (14,15,19), excluding medically treated patients
(18,19,21). The unavoidable consequences of these
gaps in knowledge are that American and European
guidelines on valvular diseases consider AF a Class II
(debated) indication for mitral surgery, with low
levels of evidence, advocating for new and more
powerful studies (4,5,22,23). Furthermore, AF guide-
lines highlight differences between paroxysmal and
persistent AF (22,24), raising additional uncertainties
on potential outcome or therapeutic implication dif-
ferences in DMR.
To address these gaps in our knowledge, a large
cohort gathered at multiple international centers
is needed to limit potential selection biases charac-
terizing individual single-center studies or national
health care systems. Accordingly, we took advantage
of the MIDA (Mitral Regurgitation International
Database), the largest international registry of pure
severe DMR patients consecutively diagnosed
by echocardiography at the European and North
American centers. We aimed to define the prevalence,
clinical context, and prognostic implications of
paroxysmal and persistent AF at diagnosis of DMR
and during long-term follow-up.METHODS
A fully detailed Methods section is available
in the Online Appendix. A more concise
version is reported in the following text.
STUDY DESIGN. The MIDA is an international
registry based on routine clinical practice and
assembled by merging a series of prospec-
tively assembled electronic institutional databases
(20,25–29). All centers participating in the registry are
recruiting centers. Patients were screened for MIDA if
they had flail mitral leaflet diagnosed by echocardio-
gram at 1 of the participating centers between 1980
and 2005 according to each center’s database.
INCLUSION AND EXCLUSION CRITERIA. The MIDA
inclusion/exclusion criteria are: 1) DMR diagnosis
and flail leaflet at the index transthoracic echocardi-
ography, which had to be performed at any of the
participating centers; 2) comprehensive clinical/
instrumental evaluation at index echocardiography;
3) exclusion of ischemic/functional regurgitation; and
4) absence of significant concomitant aortic disease,
mitral stenosis, active endocarditis, congenital
diseases, and previous valve surgery. For the specific
purpose of the present study, cardiac rhythm had to
be ascertained by an electrocardiogram, and patients
showing pacemaker rhythm or rhythm other than
sinus/AF were excluded. To obtain the most repro-
ducible definition, AF was defined based on temporal
patterns (24).
ECHOCARDIOGRAPHY. Because the MIDA Registry
focuses on routine clinical practice, echocardio-
graphic data were analyzed as collected at the time
of echocardiography performed without subsequent
modification or central review (see the Online
Appendix).
BASELINE EVALUATION AND FOLLOW-UP. The
patients’ baseline clinical characteristics reported in
the MIDA are those collected by personal physicians
at the time of the echocardiogram, and were reported
unaltered.
Subsequent patient management after the baseline
echocardiogram (including if and when indicating
surgery) was independently determined by personal
physicians. Follow-up events recorded in the
MIDA are those specifically linked to the natural his-
tory of DMR (4,5). Those events were ascertained by
clinical note reviews and/or telephone calls with
physicians, patients, and (if necessary) next of kin by
investigators unaware of the subsequent analyses.
All patients provided informed consent for anon-
ymous publication of clinical data for scientific
TABLE 1 Study Population
Overall Patient
Population
(N ¼ 2,425)
Sinus Rhythm
(n ¼ 1,646)
Paroxysmal Atrial
Fibrillation
(n ¼ 317)
Persistent Atrial
Fibrillation
(n ¼ 462) p Value
Age, yrs 67  13 65  13 68  13* 73  11* <0.0001
Male 1,732 (71) 1,200 (73) 223 (71) 309 (67)* 0.002
Body surface area, m2 1.9  0.2 1.9  0.2 1.9  0.2 1.9  0.3 0.32
Asymptomatic 1,625 (67) 1,196 (73) 203 (64)* 226 (49)* <0.001
Heart rate, beats/min 76  16 75  15 72  14* 84  20* <0.001
History of coronary artery disease 256 (11) 175 (11) 26 (8) 55 (12) 0.16
Diabetes 176 (7) 103 (6) 28 (9) 45 (10)* 0.008
Hypertension 973 (40) 644 (39) 145 (46) 184 (40) 0.29
Chronic kidney disease 81 (4) 51 (3) 13 (4) 17 (4) 0.60
Left atrial diameter, mm 50  9 48  8 52  9* 56  10* <0.001
Left ventricular end-diastolic diameter, mm 58  7 58  7 59  7 59  8* 0.029
Left ventricular end-systolic diameter, mm 36  7 35  6 37  7* 38  8* <0.001
Left ventricular ejection fraction, % 64  10 65  9 63  10* 61  12* <0.001
Severe mitral regurgitation 2,275 (94) 1,532 (94) 302 (96) 441 (96) 0.078
Right ventricular systolic pressure, mm Hg 44  17 42  16 45  18* 48  17* <0.001
ACE inhibitors/angiotensin receptor blockers 1,018 (42) 640 (39) 140 (44) 238 (51)* <0.001
Beta-blockers 438 (18) 275 (17) 79 (25)* 84 (18) 0.004
Diuretics 838 (35) 474 (29) 120 (38)* 244 (53)* <0.001
Digoxin 571 (24) 237 (14) 97 (31)* 237 (51)* <0.001
Values are mean  SD or n (%). *p < 0.05 versus sinus rhythm.
ACE ¼ angiotensin-converting enzyme.
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266research purposes; the study was approved by the
locally appointed ethics committees.
STATISTICAL ANALYSIS AND QUALITY CONTROL OF
THE DATA. Continuous variables are expressed
as mean  1 SD, and/or as median (25th to 75th
percentile). Categorical data are reported as numbers
(percentages).
The primary endpoint was total mortality, while
the secondary endpoint was death from cardiovas-
cular causes (CVD). Endpoints were analyzed: 1)
overall (i.e., considering the entire follow-up period
from diagnosis and including the post-surgical phase
if mitral operation was performed); 2) under medical
(nonsurgical) follow-up (i.e., starting the observation
at diagnosis and censoring the follow-up at the time
of surgery if this was performed); and 3) during
the post-operative follow-up (i.e., initiating the
observation at the time of surgery and including the
immediate post-surgical phase).
Rates of events were estimated by the Kaplan-
Meier method. Landmark analysis was performed to
take into account the impact of the length of time
from diagnosis to surgery on outcome. Patients were
grouped into those who had surgery before the
landmark point (set at 3, 6, and 12 months from
diagnosis), or medically managed up to the landmark
point (followed by surgery whenever considered
indicated). Patients deceased or censored prior to the
landmark point were excluded (30).The instantaneous rate of death across follow-up
was quantified by hazard functions methodology (31).
Cox proportional hazards analysis was used to
assess predictors of events; variables reaching
p < 0.10 were entered in a multivariate model.
To assess the influence of surgery and AF during
follow-up on outcome, we performed time-dependent
proportional hazards analysis.
Because surgery is a competing risk event when
analyzing survival under medical management (and
so is non-CVD when analyzing CVD), we also
performed competing risk analysis (32). A p <0.05
was considered significant.
Although the MIDA Registry does not include a local
audit, data collected at each institution undergo
quality control before being merged into the database.
RESULTS
STUDY POPULATION. Of the 2,522 patients currently
included in the general MIDA Registry, 2,425 satisfied
the inclusion/exclusion criteria for the present anal-
ysis. The general baseline characteristics of the
present study population are summarized in Table 1.
The vast majority of patients presented with no
symptoms and normal left ventricular function at the
time of the index echocardiogram. The low preva-
lence of coronary artery disease is consistent with the
nonischemic etiology of the regurgitation. Flail leaflet
was idiopathic in 2,266 (93%) patients, and caused by
FIGURE 1 Excess Risk of Mortality Linked to Atrial Fibrillation
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Forest plot illustrating the excess risk of overall mortality linked to paroxysmal and persistent atrial fibrillation (AF) in subgroups of patients
pre-specified according to the presence/absence of guideline-endorsed predictors of outcome in degenerative mitral regurgitation. The
hazard ratio (HR) is set at 1 for sinus rhythm and adjusted for age, sex, and the effects of surgery when performed. The p for interaction is
reported on the right. The size of the bullets reflects the sample size of patients belonging to each specific subgroup, which is also reported
as a number. The entire follow-up from diagnosis (including the post-surgical period in patients who underwent mitral operation) is
considered in this specific analysis. See also the Methods section for more details. EF ¼ ejection fraction; ESD ¼ end-systolic diameter;
LA ¼ left atrium; LV ¼ left ventricular; RVSP ¼ right ventricular systolic pressure.
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267previous endocarditis in the remaining 159 (7%).
Isolated involvement of the posterior leaflet was
diagnosed in 1,921 patients (79%) and of the anterior
leaflet in 345 (14%), while both leaflets were involved
in 159 patients (7%).
Patients’ baseline characteristics according to the
type of rhythm are also listed in Table 1. Although
the vast majority of patients (68%) (n ¼ 1,646)
presented in normal sinus rhythm (SR) at the time ofechocardiographic diagnosis of DMR, AF (either
persistent or paroxysmal) was present in 779 patients
(32%). Median duration of persistent AF recorded at
index evaluation was 47 months (interquartile range:
7 to 74 months). As expected, a progressive impair-
ment in baseline clinical instrumental parameters
was recorded when comparing patients in SR to those
presenting with paroxysmal and eventually persis-
tent AF (Table 1).
CENTRAL ILLUSTRATION Long-Term Prognostic Implications of Atrial Fibrillation Complicating Degenerative
Mitral Regurgitation
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Grigioni, F. et al. J Am Coll Cardiol. 2019;73(3):264–74.
Long-term estimated overall survival (A) and survival free from cardiovascular (CV) disease (B) according to cardiac rhythm at degenerative mitral regurgitation
diagnosis. The entire follow-up from diagnosis is considered in this specific Kaplan-Meier analysis (including the post-surgical period in patients who underwent mitral
operation). AF ¼ atrial fibrillation.
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FIGURE 2 Long-Term Survival in Degenerative Mitral Regurgitation Using Landmark Analysis
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Patients were grouped into those who had surgery before the landmark point (i.e., within 6 months from diagnosis), or medically managed up to the landmark point with
surgery performed later on during follow-up when considered indicated. Patients deceased or censored prior to 6 months were excluded. See also the Methods section.
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269LONG-TERM PROGNOSTIC IMPLICATIONS OF AF.
During a mean overall follow-up of 9.1  5.4 years
(median 9 years; 25th to 75th percentile 6 to 12 years),
933 deaths occurred, of which 598 (64%) were
cardiovascular. Surgery was eventually performed in
1,889 patients (78%) (in 1,463 patients within
6 months of diagnosis). Estimated overall survival at
5, 10, 15, and 20 years was 80  1%, 67  1%, 53  1%,
and 41  2%, respectively. The overall incidence of
new AF during follow-up in SR and paroxysmal AF
(n ¼ 458) was, respectively, 24  1% and 36  3% at 10
years (p < 0.001).
At Cox proportional hazard analysis, paroxysmal
(adjusted hazard ratio [HR]: 1.51; 95% confidence
interval [CI]: 1.24 to 1.82) and persistent AF at diag-
nosis (adjusted HR: 2.12; 95% CI: 1.82 to 2.46) were
independent of age, sex, and whether surgery was
performed or not associated with an increased risk of
death (p values <0.0001). When all Class I indicators
for surgery indicated by ACC/AHA guidelines (i.e.,
symptoms, LVEF #60%, left ventricular end-systolic
diameter $40 mm) were additionally factored into
the multivariable model reported in the previous text,the negative prognostic implications on mortality
were retained both for paroxysmal (adjusted HR:
1.46; 95% CI: 1.20 to 1.76) and persistent (adjusted
HR: 1.94; 95% CI: 1.66 to 2.24) AF (p # 0.001). When
further adjusted for associated comorbidities, parox-
ysmal and persistent AF at diagnosis retained their
prognostic significance independently of peripheral
vascular disease (p < 0.0001), chronic kidney disease
(p < 0.0001), diabetes (p < 0.0001), lung disease
(p < 0.0001), and/or cancer (p < 0.0001). Surgery as a
time-dependent variable was associated with better
survival regardless of all baseline characteristics and
rhythm (adjusted HR for surgery performed: 0.26;
95% CI: 0.23 to 0.30; p < 0.0001). The absence of
significant interaction between surgery performed
and AF (or between the time of surgery and AF)
(p $ 0.36) confirmed the beneficial effects of surgery,
particularly when performed early in all subsets of
rhythm (Online Tables 1 and 2, Online Figure 1).
Figure 1 shows the Forest plot in selected sub-
groups of patients pre-specified according to the
presence/absence of outcome predictors endorsed by
current scientific guidelines. The prognostic value of
FIGURE 3 Long-Term Survival in Degenerative Mitral Regurgitation After Surgery
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Long-term survival (left) and survival free from cardiovascular disease (CVD) (right) after surgery (Kaplan-Meier analysis). In these analyses,
the observation started at the time of mitral valve operation. See also the statistical analysis section for a more detailed explanation.
AF ¼ atrial fibrillation.
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270AF was particularly evident in patients without Class I
indications for surgery, when additional indicators of
outcome helping decision-making are currently most
needed. The Central Illustration depicts estimated
20-year overall survival (panel A) and survival free
from CVD (panel B) according to the type of rhythm at
diagnosis. The landmark analysis (Figure 2) confirms
the negative prognostic implications of AF regardless
of whether patients within the first 6 months from
diagnosis underwent surgery or medical management
followed by surgery whenever considered indicated
(surgery was eventually performed in 1,827 patients
[80%]). Notably, in all rhythm subsets, patients
operated within 6 months from diagnosis showed a
better survival compared with those initially assigned
to medical management (Figure 2). Those results were
confirmed setting the landmark point at 3 or
12 months (p # 0.001).
Cox proportional hazard analysis showed that
paroxysmal (adjusted HR: 1.78; 95% CI: 1.41 to 2.25)
and persistent AF (HR: 2.55; 95% CI: 2.12 to 3.06) at
diagnosis were independent of age, sex, and the
effects of surgery, associated with an increased risk of
CVD (p < 0.0001). Analogously, the transition from SR
to AF during follow-up was independent from age,
symptoms, sex, ejection fraction, baseline rhythm,
and surgery performed associated with an increased
risk of death (adjusted HR for AF occurrence: 1.24;
95% CI: 1.05 to 1.46; p ¼ 0.010).When CVD and non-CVD were considered in a
competitive risk analysis, the independent negative
prognostic implications of AF at diagnosis were
retained (p # 0.001) (Online Tables 3 to 5). The same
applied considering death and surgery as competing
endpoints (Online Table 6).
PROGNOSTIC IMPLICATIONS OF AF AT THE TIME OF
MITRAL SURGERY AND DURING LONG-TERM
POST-SURGICAL OUTCOME. A perioperative death
(defined as death within 30 days of the operation)
occurred in 39 of 1,189 patients who underwent
surgery (2.06%). Patients in SR at the time of surgery
had an operative mortality of 1.67% (n ¼ 21 of 1,257).
The operative mortality for paroxysmal AF was 2.10%
(n ¼ 5 of 238) and 3.30% for persistent AF (n ¼ 13 of
394) (p ¼ 0.16). Mitral repair was accomplished in
1,664 patients (88%). In 1 patient operated outside of
the MIDA centers, the surgical report could not be
retrieved, and consequently, the type of procedure
(repair vs. replacement) could not be ascertained. The
rate of repair was 90% in patients in SR (n ¼ 1,130 of
1,257), 90% in those with paroxysmal AF (n ¼ 213 of
238), and 82% in patients with persistent AF
(n ¼ 321 of 394) (p < 0.001). An associated Maze
procedure was performed in 62 patients (41 patients
with persistent AF).
In patients in SR without any Class I indication
for surgery (e.g., symptoms, and/or left ventricular
ejection fraction #60%, and/or end-systolic
FIGURE 4 Hazard Functions
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Hazard functions depicting the instantaneous rate of death across follow-up in patients
treated medically (A) and after surgery (B). AF ¼ atrial fibrillation.
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271diameter $40 mm), operative mortality was 0.69%
overall (4 of 580), and 2.67% in those either with a
history of AF and/or any Class I indication for surgery
(35 of 1,309) (p ¼ 0.002).
During a post-surgical follow-up of 9.1  4.8 years
(median 9 years [interquartile range: 6 to 12 years]),
534 deaths occurred (including the perioperative
deaths), of which 341 were CVDs (64%). The 10-year
post-surgical incidence of AF was 23  1% in those
operated in SR and 36  3% in those operated with
paroxysmal AF (p < 0.001).
Confining the analysis to the post-operative phase,
paroxysmal (adjusted HR: 1.58; 95% CI: 1.21 to 2.04;
p ¼ 0.001) and persistent AF (adjusted HR: 2.06;
95% CI: 1.70 to 2.50; p < 0.0001) were associated with
a higher risk of mortality regardless of age,
sex, EuroSCORE II, the type of surgery (repair/
replacement), and the association of a Maze proced-
ure with the mitral operation.
The results were further confirmed by selecting
post-surgical CVD as the endpoint of the previously
mentioned model (adjusted HR for paroxysmal
AF: 1.92; 95% CI: 1.38 to 2.62; p < 0.001; adjusted
HR for persistent AF: 2.34; 95% CI: 1.83 to 2.98;
p< 0.001). Overall survival and survival free from CVD
after surgery according to rhythm at the time of the
operation are depicted in Figure 3. The instantaneous
rate of death across time after surgery and under
medical management is depicted in Figure 4.
DISCUSSION
The present study used the MIDA, the largest multi-
center international registry enrolling consecutive
patients with pure, isolated, severe DMR diagnosed
by echocardiography. We found that AF, either
paroxysmal or persistent, is common at DMR diag-
nosis and is not an isolated phenomenon. It is asso-
ciated with older age and more severe clinical and
echocardiographic presentation of DMR. Despite
these collinearities, the unequaled sample size of
our cohort demonstrates that the magnitude of the
mortality risk progressively increases from sinus to
paroxysmal to persistent AF independently of all
underlying patient characteristics. Although the
mortality risk is reduced by surgery in all subsets of
patients (vs. the risk under medical management), we
also found that paroxysmal and persistent AF are
linked to excess post-surgical mortality that persists
long-term throughout the follow-up. Although
current guidelines mainly focus on paroxysmal AF,
the findings of the present study suggest that prompt
surgery should be considered in patients with DMR
and AF of any type.In routine clinical practice, DMR and AF are often
diagnosed separately, but as the present study
shows, the 2 pathological disorders are interlinked in
many cases (11). In addition, due to the aging and
increase in the general population, the prevalence,
complications, and direct costs of both conditions
are expected to increase significantly in the near
future (1).
About one-third of the MIDA registry patients with
severe DMR in this study had a medical history
remarkable for AF (Table 1). AF is the most common
sustained cardiac arrhythmia, occurring in 1% to 2%
of the general population (33,34), and DMR is another
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272public health problem whose burden is expected to
increase in line with an aging population (1). Some-
what surprisingly, the exact prevalence of AF
complicating isolated pure severe DMR is still
debated, ranging in previous studies from 20% to 55%
(11,15,18–21,35). This is the first study providing data
on the prevalence of AF at the time of DMR diagnosis
derived from a large sample size collected consecu-
tively and internationally (and, consequently, at
lower risk of referral bias). By highlighting the
magnitude of the epidemiological link between these
2 costly and lethal conditions (assessed by adopting
the most recent diagnostic criteria) (22,24), our find-
ings call for prompt preventive and therapeutic stra-
tegies aimed at properly managing this already
enormous but still growing number of patients (3).
Our study provides multiple and convergent
results indicating that AF is associated with a higher
risk of death. Since we recorded a more significant
impairment of associated clinical/instrumental
parameters in patients with AF (Table 1), whether AF
may merely represent an indicator of a more severe
underlying cardiac disease or conversely, once
established, it independently contributes to disease
progression remains unclear. These uncertainties
apply more in general to AF from any etiology,
including nonvalvular AF (36), and cannot be defini-
tively answered without a prospective randomized
study. Nevertheless, our results provide major evi-
dence for the management of DMR until prospective
studies are—hopefully—performed. Indeed, for
the first time, we showed that AF maintained an in-
dependent association with a higher mortality in
almost all subgroups of patients pre-defined accord-
ing to the presence/absence of all risk factors
currently endorsed by scientific guidelines (4,5),
either taken alone or in combination (Figure 1). In this
respect, the greater prognostic value of AF in patients
without concomitant Class I indications for surgery is
of particular value, because these are the patients for
whom further data on decision-making are most
needed. At the same time, the smaller magnitude of
the prognostic impact of AF in patients already
showing the severe consequences of volume overload
(symptomatic patients who have already developed
ventricular dysfunction complicated by pulmonary
hypertension) should be considered expected,
because these patients are already at the highest risk
and their management is already established. Finally,
the independent association between AF and CVD
presents additional arguments toward considering
even paroxysmal AF a marker of an impelling unfa-
vorable adaptation to the volume overload.Concerning the surgical phase, we found a signifi-
cantly lower rate of mitral repair performed in
patients with AF compared to the repair rate obtained
in patients in SR (although the overall rate of repair in
the whole series was satisfactory, being almost 90%).
The lower rate of mitral repair in patients with AF has
been previously reported (14) and could be attributed
to the questionable perception of a diminished
beneficial effect of repair over replacement in this
group of patients (37,38). We also found a trend
toward higher operative mortality in patients
operated in AF, and this finding may provide addi-
tional arguments in favor of bringing forward the
surgical correction to an earlier stage. Previous
studies found a similar trend toward higher mortality
for mitral repair when performed in patients with
AF (15,18).
Although mitral surgery was beneficial indepen-
dently of patient characteristics (Online Figure 1), AF
was nevertheless linked to an unfavorable long-term
post-surgical outcome (Figures 3 and 4), which was
also confirmed at multivariate analysis (p < 0.001)
and which increased moving from SR to paroxysmal
to persistent AF. Current guidelines consider AF a
Class II indication for surgery in DMR, reflecting
current uncertainties on this topic and advocating
“additional studies with focused objectives” (5,22).
Taken together, the results of the present study make
a notable contribution in this direction.
STUDY LIMITATIONS AND STRENGTHS. We found a
high prevalence of systemic hypertension in our
study population. The epidemiological association
between hypertension and DMR has been described,
and raises the hypothesis that long-term exposure to
higher blood pressure could lead to structural
changes in the mitral valve (39). Future studies are
needed to establish whether lowering blood pressure
might reduce the risk of DMR.
Current ablation techniques are reported to be safe
(40), but the small number of procedures performed
in the present series precluded a specifically
dedicated analysis. The notable 10-year post-surgical
incidence of AF we found is in keeping with
the advice that ablation techniques should be
more liberally applied at the time of open atrial pro-
cedures (40).
Because this is not a randomized trial, we should
be prudent in concluding that operating on patients
in SR (who displayed the lowest operative mortality,
the highest rate of repair, and the most favorable
long-term post-surgical outcome) may provide
incremental beneficial effects compared with waiting
for the occurrence of AF. Nevertheless, data obtained
PERSPECTIVES
COMPETENCY IN PATIENT CARE: The develop-
ment of AF in a patient with DMR identifies a sub-
group at high risk of adverse outcomes that can be
improved with valve repair surgery.
TRANSLATIONAL OUTLOOK: More research is
needed to understand the factors associated with
onset of AF in patients with DMR and determine
whether intervention to prevent AF or correct MR
improves long-term clinical outcomes.
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273from registries provide important outcome informa-
tion, which is vital while awaiting appropriate clinical
trials. The firm observation that any type of AF
independently increases the risk of mortality should
raise the concern that once it arises, AF increases the
risk of mortality, which can only partially be reversed
by surgery.
The risk of residual confounding cannot be defini-
tively ruled out in any observational study, and the
decision to recommend surgery could be linked to
a subset of patients who are at lower risk (41).
Nevertheless, surgery showed a remarkably strong
independent association with total and CVD. The HR
did not show significant variation, although it was
tested in multiple models including up to 233 events
per variable and adjusted for all Class I triggers for
surgery (Online Tables 1 to 5). Despite a comparable
(p ¼ 0.50) EuroSCORE II (which includes a very
comprehensive and established set of cardiovascular
and noncardiovascular prognostic factors), an earlier
surgical treatment was independently associated
with a better outcome (Online Figure 1).
CONCLUSIONS
AF is a frequent complication of DMR due to flail
leaflets, present in about 30% of consecutive patients
diagnosed by transthoracic echocardiography.
Although paroxysmal and persistent AF are associ-
ated with older age and worse clinical and echocar-
diographic presentation, their progressively negative
prognostic implications are confirmed by multivari-
able analysis and in subgroup analyses. Thus, once
established, AF may either contribute to DMR diseaseprogression or unfavorably influence prognosis on its
own, or both. Furthermore, as rhythm disturbances
progress from SR to paroxysmal and to persistent AF,
the superimposed excess risk of total and cardiovas-
cular mortality is only mitigated (but not corrected)
by mitral surgery, with lower rates of repair and
worse long-term post-surgical outcomes.
Taken together, our findings indicate that
the detection of even paroxysmal AF should trigger
prompt consideration for surgery to minimize
risks under medical management and prevent sub-
optimal operative results with a reduced long-term
post-operative outcome.
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